Skip to content
(Bloomberg Opinion) -- Covid-19 has roiled the entertainment industry in ways that threaten to leave a permanent mark. Now, corporate giants such as Comcast Corp. and AT&T Inc. that have staked their futures on the space — from television and cinema, to amusement parks and sporting events — are left facing an uncomfortable choice: retrench or stay the course against increasing investor opprobrium.Comcast, the cable giant that acquired NBCUniversal’s TV networks, film studio and theme parks in 2013, is now the target of an activist shareholder, Nelson Peltz’s Trian Fund Management. The hedge fund is known for pushing needlessly bulky companies to slim down by shedding their weakest assets. In this case, that would be NBCUniversal as well as Sky, Comcast’s recently acquired European satellite-TV unit. Last year, AT&T also attracted an activist, Elliott Management Corp., concerned with the trajectory of its own satellite-TV and Hollywood assets. What the two campaigns appear to have in common is a desire to...
A recent, independent study by Neptune Wellness shows bipartisan support for legalizationLAVAL, QC, Sept. 30, 2020 /CNW Telbec/ - Neptune Wellness Solutions, Inc....
After calling the March bottom, Fundstrat's Tom Lee says he has a new level in the S&P 500 to watch....
The former head of Volkswagen's Audi luxury car division and three others went on trial Wednesday on charges related to the company's cheating on diesel car emissions tests. The proceedings represent the first criminal trial in Germany over the scandal that erupted five years ago and has cost the Volkswagen Group more than 32 billion euros ($35 billion) in fines and settlements. Rupert Stadler and the three co-defendants are charged with fraud, false certification and criminal false advertising before a court in Munich in a trial that is scheduled to include 176 sessions lasting until Dec. 20, 2022....
Valencia C. Become First LaLiga Team to Leverage Augmented Reality for Fan Activation & EngagementVANCOUVER, BC and ERIE, Pa....
The analysts covering Inovio Pharmaceuticals, Inc. (NASDAQ:INO) delivered a dose of negativity to shareholders today......
